Angioplasty with stenting in ischemic stroke when thrombolytic agents won

Original title: A Controlled Trial of Revascularization in Acute Stroke. Reference: Martin Roubec et al. Radiology. 2012;Epub ahead of print.

One of the most crucial forecast factors in patients undergoing acute ischemic stroke, stroke caused by a blockage in a brain artery, is the time window to recanalization. 

Thrombolytic agents have been proved useful but not always achieve reperfusion and may sometimes be contraindicated. The goal of this study was to analyze the safety and efficacy of brain angioplasty in acute ischemic stroke in patients with failed thrombolysis and those ineligible to receive it. 

Within 4.5 hours of onset, from 131 patients (all had a blockage in the middle cerebral artery detected by CT) 75 received thrombolytic agents (IVTs). From these 75, only 26 patients successfully re-opened the blocked artery, the remaining 49 either received brain angioplasty with stenting (n=23) or were assigned to the control group (n=26).

The 56 patients originally ineligible for IVTs were also divided to receive brain angioplasty with stenting (n=31) or to the control group (n=25). Primary end point was favorable outcome defined as a 0 to 2 score in the modified Rankin scale at three months. 

Brain angioplasty outcome was superior compared to the control group both for patients with failed thrombolysis (43.5% vs. 15.4% p=0.034 respectively) and patients with contraindication (45.2% vs. 8% p=0.004 respectively).

Symptomatic bleeding rate at 24 hrs and mortality at 7 and 90 days was no different between the groups.

Conclusion 

In patients with acute ischemic stroke due to a blockage in the medial brain artery ineligible for IVTs or after failed IVT administration, brain angioplasty with stenting was safe and effective.

Editorial Comment:

In this context, angioplasty seems safe but must be validated by further randomized studies. This trial, as most of trials on stroke, analyzed heterogeneous populations. This is illustrated by the fact that stent selection was left to the operator’s criterion, which resulted in more than 8 different types of stents.

SOLACI.ORG

More articles by this author

Download the Official SOLACI-CACI 2024 Congress APP

  DOWNLOAD THE OFFICIAL APP OF SOLACI-CACI 2024 Next Wednesday marks the beginning of SOLACI-CACI 2024! Download the Congress APP and discover the unmissable program of the...

Survey on Hemodynamics Centers in Latin America – SOLACI, Stent Save a Life! and South American Society of Cardiology Initiative

The treatment of ST-segment elevation myocardial infarction (STEMI) in Latin America is highly diverse. There are notable differences between countries and even among regions...

SOLACI-SBHCI 2023 Congress Has Begun!

Let the best begin! After a year of intense work, SOLACI-SBHCI 2023 Congress—the widest, most important event for interventional cardiologists in Latin America—has kicked...

SOLACI-SBHCI 2023 Congress Has Begun!

Let the best begin! After a year of intense work, SOLACI-SBHCI 2023 Congress—the widest, most important event for interventional cardiologists in Latin America—has kicked...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....